Objective To explore the application of the Pharmaceutical Care Network Europe(PCNE)classification system for drug-related problems(DRPs)in the individualized pharmacy of blood concentration monitoring and genetic testing,so as to provide basis for standardized individualized pharmacy services.Methods The DRPs of methotrexate were analyzed using the PCNE classification system(version 9.1)in patients undergoing methotrexate blood concentration as well as genetic monitoring,and the presence of DRPs,causes,intervention interventions,and acceptance were analyzed.Results In the present study,out of a total of 738 methotrexate visits to the pharmacy service in 117 patients,244 drug-related problems were identified,85.25％of which were intervened,with 208 intervention acceptances,giving an intervention acceptance rate of 73.56％.These(proba-ble)adverse drug events(n=188,77.05％)were DRP FAQs,and one problem could have multiple causes,with inappropriate combination of drugs(27.08％)as the main cause.Conclusion The introduction of the PCNE classification system helps to standardize pharmacy services in the individualized administration of methotrexate,establish a perfect precision pharmacy service system,enhance the pharmacy service capacity,and promote the rational use of medication.
pharmaceutical care network Europedrug-related problemmethotrexateblood concentrationgene polymor-phismpharmaceutical care
万方数据
维普
